Disease-modifying Properties of Lithium in the Neurobiology of Alzheimer's Disease
Disease-modifying Properties of Lithium in the Neurobiology of Alzheimer's Disease: a Double-blind, Placebo-controlled Prevention Study in Elderly Patients With Mild Cognitive Impairment
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
SP
-
Sao Paulo, SP, Brazil, 05403-010
- Institute of Psychiatry, Faculty of Medicine - University of Sao Paulo
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patients with amnestic mild cognitive impairment;
- age: 60 to 80 years-old;
Exclusion Criteria:
- sensory deficiencies that might preclude the administration of cognitive tests;
- active major psychiatry disorder;
- unstable clinical conditions such as cardiac insufficiency, uncontrolled diabetes mellitus, renal failure;
- previous use of lithium salts;
- concurrent participation in other clinical trial or intervention studies;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Lithium
Patients received low doses of lithium salts (from 150 mg to 450 mg of lithium salts daily) to achieve sub-therapeutic lithium levels (target serum lithium level of 0,25 - 0,5 mEq/L).
Lithium doses were administered twice a day.
Lithium doses were titrated to achieve the target serum lithium levels within the first two weeks after study recruitment.
After achieving the target serum lithium level, lithium salts doses remained stable until the end of the study.
|
lithium carbonate tablets, 150 mg to 450 mg (target serum lithium level 0.25 mEq/L - 0.5 mEq/L), divided in two doses, two years.
|
|
Placebo Comparator: Placebo
Identical placebo tablets were administered twice-a-day for two years.
|
Identical placebo tablets were administered twice-a-day for two years.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
effect of lithium to delay progression of cognitive deficits in patients with amnestic MCI
Time Frame: two year
|
two year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
effect of lithium on CSF levels of Total Tau, Phosphorylated Tau and Amyloid-beta42
Time Frame: one year
|
one year
|
|
the effect of lithium on the activity of GSK3β in platelets and leukocytes drawn from peripheral blood.
Time Frame: one year
|
one year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Orestes V Forlenza, Ph.D., Department and Institute of Psychiatry, Faculty of Medicine - University of Sao Paulo
- Study Director: Wagner F Gattaz, Ph.D., Department and Institute of Psychiatry, Faculty of Medicine - University of Sao Paulo
Publications and helpful links
General Publications
- Forlenza OV, Radanovic M, Talib LL, Gattaz WF. Clinical and biological effects of long-term lithium treatment in older adults with amnestic mild cognitive impairment: randomised clinical trial. Br J Psychiatry. 2019 Nov;215(5):668-674. doi: 10.1192/bjp.2019.76.
- Aprahamian I, Santos FS, dos Santos B, Talib L, Diniz BS, Radanovic M, Gattaz WF, Forlenza OV. Long-term, low-dose lithium treatment does not impair renal function in the elderly: a 2-year randomized, placebo-controlled trial followed by single-blind extension. J Clin Psychiatry. 2014 Jul;75(7):e672-8. doi: 10.4088/JCP.13m08741.
- Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry. 2011 May;198(5):351-6. doi: 10.1192/bjp.bp.110.080044.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurocognitive Disorders
- Neurodegenerative Diseases
- Dementia
- Tauopathies
- Cognition Disorders
- Alzheimer Disease
- Cognitive Dysfunction
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Enzyme Inhibitors
- Tranquilizing Agents
- Psychotropic Drugs
- Antidepressive Agents
- Antimanic Agents
- Lithium Carbonate
Other Study ID Numbers
Other Study ID Numbers
- OVForlenza-Lithium
- 554535/2005-0 (Other Grant/Funding Number: Conselho Nacional de Pesquisa Científica)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.